MA47719A - Esketamine pour le traitement de la dépression - Google Patents
Esketamine pour le traitement de la dépressionInfo
- Publication number
- MA47719A MA47719A MA047719A MA47719A MA47719A MA 47719 A MA47719 A MA 47719A MA 047719 A MA047719 A MA 047719A MA 47719 A MA47719 A MA 47719A MA 47719 A MA47719 A MA 47719A
- Authority
- MA
- Morocco
- Prior art keywords
- esketamine
- depression
- treatment
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 229960000450 esketamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609504P | 2017-12-22 | 2017-12-22 | |
| US201862663219P | 2018-04-26 | 2018-04-26 | |
| US201862663206P | 2018-04-26 | 2018-04-26 | |
| US201862667406P | 2018-05-04 | 2018-05-04 | |
| US201862675846P | 2018-05-24 | 2018-05-24 | |
| US201862755905P | 2018-11-05 | 2018-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47719A true MA47719A (fr) | 2020-01-15 |
Family
ID=65003585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047719A MA47719A (fr) | 2017-12-22 | 2018-12-21 | Esketamine pour le traitement de la dépression |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11707440B2 (fr) |
| EP (1) | EP3501542B1 (fr) |
| JP (3) | JP7807870B2 (fr) |
| KR (2) | KR20200113197A (fr) |
| CN (2) | CN112423789A (fr) |
| AU (2) | AU2018282466A1 (fr) |
| BR (1) | BR112020012473A2 (fr) |
| CA (1) | CA3086478A1 (fr) |
| IL (2) | IL319020A (fr) |
| JO (1) | JOP20200156A1 (fr) |
| MA (1) | MA47719A (fr) |
| MX (2) | MX2020006650A (fr) |
| PH (1) | PH12020500555A1 (fr) |
| SG (1) | SG11202005896WA (fr) |
| TW (2) | TWI843711B (fr) |
| WO (1) | WO2019126108A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014240102A1 (en) | 2013-03-15 | 2015-09-17 | Janssen Pharmaceutica Nv | Pharmaceutical composition of S-ketamine hydrochloride |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| IL319020A (en) | 2017-12-22 | 2025-04-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| HUE058320T2 (hu) | 2017-12-29 | 2022-07-28 | Celon Pharma Sa | Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén |
| EP3813807A1 (fr) | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Procédé de traitement d'un trouble dépressif majeur |
| KR20210074275A (ko) | 2018-10-05 | 2021-06-21 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| WO2020178653A1 (fr) * | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Eskétamine pour le traitement de la dépression |
| EP4364812A3 (fr) * | 2019-05-31 | 2024-09-04 | Afyx Development A/S | Administration intranasale de kétamine à des patients atteints d'algie vasculaire de la face |
| AU2020324432A1 (en) * | 2019-08-05 | 2021-10-07 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| EP4021432A4 (fr) | 2019-08-28 | 2023-08-16 | Janssen Pharmaceuticals, Inc. | Eskétamine pour le traitement de patients présentant un trouble dépressif majeur, notamment la suicidalité |
| WO2021048638A1 (fr) * | 2019-09-13 | 2021-03-18 | Janssen Pharmaceuticals, Inc. | Administration intranasale d'eskétamine |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| US12268658B2 (en) | 2019-12-30 | 2025-04-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| US12478592B2 (en) | 2019-12-30 | 2025-11-25 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| WO2021137148A1 (fr) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Régime posologique à base d'eskétamine pour le traitement de troubles neuropsychiatriques ou neurologiques |
| KR20230052915A (ko) * | 2020-08-18 | 2023-04-20 | 오크우드 레버러토리즈, 엘엘씨 | 케타민을 포함하는 미소 구체 제제 및 이의 제조 방법 및 사용 방법 |
| WO2022087383A1 (fr) * | 2020-10-22 | 2022-04-28 | Tonix Pharmaceuticals Holding Corp. | Procédés de respect de randomisation pour évaluer la signification d'interventions sur des résultats dans des troubles |
| CN116942648A (zh) * | 2022-04-26 | 2023-10-27 | 宜昌人福药业有限责任公司 | 艾司氯胺酮液体制剂及其用途 |
| WO2024201274A1 (fr) * | 2023-03-24 | 2024-10-03 | Janssen Pharmaceutica Nv | Eskétamine destinée à être utilisée dans le traitement de la dépression |
| WO2024263816A2 (fr) * | 2023-06-21 | 2024-12-26 | Cristcot Llc | Développement et validation de mesure d'impact de symptômes d'une maladie hémorragique |
| WO2025106879A1 (fr) * | 2023-11-15 | 2025-05-22 | Gilgamesh Pharmaceuticals, Inc. | Méthodes de traitement de troubles psychiatriques ou de la douleur à l'aide de (r)-2-(4-fluorophényl)-2-(méthylamino) cyclohexan-1-one ou de sels pharmaceutiquement acceptables de ceux-ci |
| WO2025160542A1 (fr) * | 2024-01-26 | 2025-07-31 | Inesket Llc | Formulation de pulvérisation nasale de kétamine et méthodes d'utilisation |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10025A (en) | 1853-09-20 | Improvement in turbines | ||
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| ATE245024T1 (de) | 1995-02-24 | 2003-08-15 | Stuart L Weg | Anwendung von ketamin zur entgiftung |
| WO1997007750A1 (fr) | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments |
| FR2739294B1 (fr) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | Embout nasal de securite |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| FR2764807B1 (fr) | 1997-06-18 | 1999-08-20 | Valois Sa | Dispositif de distribution nasale d'un produit fluide ou pulverulent |
| WO2000004875A2 (fr) | 1998-07-24 | 2000-02-03 | Seo Hong Yoo | Preparation de dosages de solution claire aqueuse avec des acides biliaires |
| US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| EP1103256A1 (fr) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique |
| CA2423354C (fr) | 2000-09-20 | 2009-12-15 | Lee Shahinian Jr. | Preparations et medications nasales, inhalables et ophtalmiques locales a conservation spontanee |
| US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| EP1551393A4 (fr) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| JP2006510618A (ja) | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス，インコーポレーテッド | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
| US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
| EP2526987A3 (fr) | 2005-06-01 | 2013-04-24 | SHL Group AB | Dispositif pour administrer un médicament |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| WO2007123945A2 (fr) | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Dispositif monodose de distribution intrapulmonaire de médicaments |
| AU2007253684A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2008151179A2 (fr) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Phénéthylamines substituées |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| JP6133772B2 (ja) | 2010-06-15 | 2017-05-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み治療用の医薬配合物 |
| WO2013003669A2 (fr) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, méthodes d'utilisation et méthodes de traitement |
| EP2766339B1 (fr) | 2011-10-14 | 2021-06-09 | The United States Of America, as represented by the Secretary, Department of Health & Human Services | Utilisation de la (2r, 6r)-hydroxynorkétamine et d'autres métabolites hydroxylés stéréo-isomères de la (r,s)-kétamine dans le traitement de la dépression et de la douleur neuropathique |
| EP2780467B1 (fr) | 2011-11-14 | 2018-10-17 | Alfasigma S.p.A. | Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| WO2013138322A1 (fr) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements |
| AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US20140057988A1 (en) | 2012-08-23 | 2014-02-27 | Stuart WEG | Anxiolytic composition, formulation and method of use |
| FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
| NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
| ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
| MX370506B (es) | 2013-04-12 | 2019-12-16 | Icahn School Med Mount Sinai | Método para tratar trastorno de estrés post-traumático. |
| EP3035918B1 (fr) | 2013-08-26 | 2021-06-30 | Amorsa Therapeutics, Inc. | Dose orale à couche unique de kétamine neuro-atténuante |
| US9872841B2 (en) | 2013-09-13 | 2018-01-23 | National University Corporation Chiba University | Application of R-ketamine and salt thereof as pharmaceuticals |
| CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
| WO2015101693A1 (fr) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Compositions et préparations combinées pour le traitement des douleurs oropharyngées |
| WO2015108985A1 (fr) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprenant de la kétamine pour le traitement d'un trouble du spectre de l'autisme |
| US10335379B2 (en) | 2014-04-17 | 2019-07-02 | Develco Pharma Schweiz Ag | Oral dosage forms of ketamine |
| BR112016025691B1 (pt) | 2014-05-04 | 2022-01-04 | Firmenich S.A. | Método para adoçar produtos alimentícios e de bebida e tais produtos |
| FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
| CA2957926A1 (fr) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Methode de traitement de la depression |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20180015054A1 (en) | 2014-12-31 | 2018-01-18 | Icahn School Of Medicine At Mount Sinai | Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium |
| CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
| US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
| IL319020A (en) | 2017-12-22 | 2025-04-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
-
2018
- 2018-12-18 IL IL319020A patent/IL319020A/en unknown
- 2018-12-18 CA CA3086478A patent/CA3086478A1/fr active Pending
- 2018-12-18 SG SG11202005896WA patent/SG11202005896WA/en unknown
- 2018-12-18 JO JOP/2020/0156A patent/JOP20200156A1/ar unknown
- 2018-12-18 KR KR1020207021196A patent/KR20200113197A/ko active Pending
- 2018-12-18 CN CN201880090058.6A patent/CN112423789A/zh active Pending
- 2018-12-18 MX MX2020006650A patent/MX2020006650A/es unknown
- 2018-12-18 JP JP2020534520A patent/JP7807870B2/ja active Active
- 2018-12-18 CN CN202311355796.8A patent/CN117531017A/zh active Pending
- 2018-12-18 KR KR1020247000937A patent/KR20240011237A/ko not_active Ceased
- 2018-12-18 WO PCT/US2018/066143 patent/WO2019126108A1/fr not_active Ceased
- 2018-12-18 IL IL275482A patent/IL275482B1/en unknown
- 2018-12-18 BR BR112020012473-7A patent/BR112020012473A2/pt unknown
- 2018-12-18 US US16/956,403 patent/US11707440B2/en active Active
- 2018-12-21 EP EP18215651.3A patent/EP3501542B1/fr active Active
- 2018-12-21 AU AU2018282466A patent/AU2018282466A1/en not_active Abandoned
- 2018-12-21 TW TW107146335A patent/TWI843711B/zh active
- 2018-12-21 TW TW112130258A patent/TW202415363A/zh unknown
- 2018-12-21 MA MA047719A patent/MA47719A/fr unknown
-
2020
- 2020-06-18 PH PH12020500555A patent/PH12020500555A1/en unknown
- 2020-07-13 MX MX2023012450A patent/MX2023012450A/es unknown
-
2023
- 2023-07-05 US US18/347,393 patent/US20240000728A1/en not_active Abandoned
- 2023-10-06 JP JP2023174444A patent/JP2024001204A/ja not_active Withdrawn
-
2024
- 2024-10-17 AU AU2024227438A patent/AU2024227438A1/en active Pending
- 2024-12-20 US US18/991,118 patent/US20250332121A1/en active Pending
-
2025
- 2025-10-15 JP JP2025173453A patent/JP2026027257A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3494142A4 (fr) | Anticorps anti-siglec-7 pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3503890A4 (fr) | Utilisation de la pridopidine pour le traitement des dystonies | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3362065A4 (fr) | Polythérapie pour le traitement de malignités | |
| EP3288592A4 (fr) | Utilisation de cannabidiol pour le traitement de spasmes infantiles | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3328374A4 (fr) | Antagonistes de la glutamine pour le traitement de déficits cognitifs | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3383497A4 (fr) | Nouveaux anticorps pour le traitement de cancers | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome |